CA2595063C - Emulsified composition for dilution and cancer vaccine composition - Google Patents

Emulsified composition for dilution and cancer vaccine composition Download PDF

Info

Publication number
CA2595063C
CA2595063C CA2595063A CA2595063A CA2595063C CA 2595063 C CA2595063 C CA 2595063C CA 2595063 A CA2595063 A CA 2595063A CA 2595063 A CA2595063 A CA 2595063A CA 2595063 C CA2595063 C CA 2595063C
Authority
CA
Canada
Prior art keywords
weight
ester
fatty acid
emulsified composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2595063A
Other languages
French (fr)
Other versions
CA2595063A1 (en
Inventor
Koichi Saito
Yusuke Okawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CA2595063A1 publication Critical patent/CA2595063A1/en
Application granted granted Critical
Publication of CA2595063C publication Critical patent/CA2595063C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof.
The present invention relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a particular surfactant, a particular emulsifier, and a water phase. The present invention also relates to a cancer vaccine composition or specific CTL
inducer obtained by freshly diluting and mixing a water phase comprising a cancer antigen peptide or a dimer thereof with the emulsified composition for dilution.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

DESCRIPTION
EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE
COMPOSITION
Technical Field The present invention belongs to the field of cancer immunotherapy and relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, having cytotoxic T cell induction activity. More specifically, the present invention relates to an emulsified composition for lo diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a surfactant, an emulsifier, and a water phase, and occurring in the form of a stable W/0 emulsion. The present invention also relates to a cancer vaccine composition or specific cytotoxic T cell inducer, comprising a particular ester, a surfactant, an emulsifier, and a water phase comprising a cancer antigen peptide consisting of a particular amino acid sequence or a dimer thereof, and occurring in the form of a stable W/0 emulsion.
Background Art In the elimination of cancer cells, virus-infected cells and the like by the living body, cellular immunity, particularly cytotoxic T cells (hereinafter referred to as CTL) play an important role. CTL recognizes the complex formed on cancer cells by a cancer antigen protein-derived antigen peptide (cancer antigen peptide) and MHC (Major Histocompatibility Complex) class I antigen (in the case of humans, referred to as HLA antigen), and attacks/destroys the cancer cells.
As a representative example of the cancer antigen protein, those described in the table of Immunity, Vol.10, page 281, 1999 can be mentioned. Specifically, gp100 and MART-1, which are melanocyte tissue specific proteins, and melanosome proteins such as tyrosinase can be mentioned. As the cancer antigen protein other than melanoma, cancer markers such as CEA, PSA, and HER2/neu can be mentioned. TERT, whose expression increases in cancer, and the like can also be mentioned. Furthermore, WT1, ak 02595063 2007-07-17 which is highly expressed in many types of cancer, is also known as a novel cancer antigen protein in leukemia and solid cancers.
The cancer antigen peptide is a peptide resulting from processing of a cancer antigen protein by intracellular protease.
As stated above, a complex of this resulting cancer antigen peptide and MHC class I antigen (HLA antigen) is presented to the cell surface and recognized by CTL. However, in developing a cancer immunotherapeutic agent (cancer vaccine) utilizing cancer cell destruction by CTL, it has been difficult to efficiently induce CTL using a cancer antigen peptide alone, because of the generally low immunogenicity. Therefore, there is a demand for the development of a preparation capable of stimulating CTL
induction.
To this end, many investigations have been conducted regarding preparations that stimulate CTL induction.
Particularly, many investigations have been conducted regarding emulsion type preparations.
Generally, there are different types of emulsion preparations: 0/W emulsions and W/0 emulsions.
In the case of 0/W emulsions, the peptide that serves as the antigen cannot be retained in the inner phase, and therapeutically effective specific CTL induction activity is not exhibited.
In the case of W/0 emulsions, in which the water phase serves as the inner phase, excellent CTL induction activity is expected because the peptide that serves as the antigen is easy to retain in the inner phase, but there are many problems to be solved before they are brought into practical applications.
For example, as a W/0 emulsion for cancer antigen peptide carrier, incomplete Freund's adjuvant is known, but effective activity cannot be obtained in some cases due to insufficient stability. There have been other problems such as difficulty in administration due to high viscosity.
Incomplete Freund's adjuvant has long been known as an immunopotentiating adjuvant that causes inactivated bacteria or ak 02595063 2007-07-17 inactivated virus to be included to induce antibody production, and alternative W/0 emulsion type vaccine compositions were investigated; for example, the compositions described in Japanese Patent Kohyo publication No. HEI-7-509733, the pamphlet for International Patent Publication No. 94/20071, and Japanese Patent Kokai Publication No. HEI-9-268130 were proposed.
As a substitute for incomplete Freund's adjuvant, an application of W/O/W composite emulsion to vaccine is proposed in Japanese Patent Kokai Publication No. 2001-131087.
/o However, as a cancer antigen peptide carrier to substitute for incomplete Freund's adjuvant, no W/0 emulsion capable of therapeutically effectively activating CTL induction is known.
Generally, because cancer antigen peptides are low-molecular compounds, it is not easy to keep them stable in W/0 emulsion. Furthermore, it is feared that the cancer antigen peptide undergoes degradation, aggregation and the like due to the energy during emulsification. Furthermore, cancer antigen peptides range from highly water-soluble ones to slightly soluble ones depending on the amino acid sequence thereof.
Therefore, there is a demand for the development of a cancer vaccine based on a highly versatile W/0 emulsion that therapeutically effectively stimulates CTL induction, irrespective of the properties of the cancer antigen peptide.
An object of the present invention is to provide an emulsified composition for dilution for preparing a cancer vaccine composition that exhibits effective CTL induction activity in vivo in various cancer antigen peptides, and is of low viscosity and excellent stability. Another object of the present invention is to provide a method of preparing a novel cancer vaccine that specifically stimulates CTL induction in vivo according to the cancer antigen peptide contained, using the above-described emulsified composition for dilution, and the composition.
Disclosure of the Invention The present inventors found that by diluting various ak 02595063 2007-07-17 peptides known as cancer antigens with a particular emulsified composition comprising a particular ester and a particular surfactant, CTL induction activity specific for each antigen can be exhibited, irrespective of the type and properties of the peptide, conducted further diligent investigations, and completed the present invention.
Accordingly, the present invention encompasses the following modes of embodiment:
[1] An emulsified composition for diluting a cancer antigen /o peptide having 8 to 12 amino acids or a dimer thereof, comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C, at 50 to 90% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
D) water at 5 to 20% by weight.
[2] An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C, at 50 to 90% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C, at 0 to 20% by weight; and D) water at 5 to 20% by weight.
[3] The emulsified composition for dilution described in [2], comprising:
ak 02595063 2007-07-17 ingredient A at 60 to 80% by weight;
ingredient B at 1 to 10% by weight;
ingredient C at 5 to 15% by weight; and ingredient D at 5 to 20% by weight.
[4] The emulsified composition for dilution described in any of [1] to [3], wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm.
[5] The emulsified composition for dilution described in any of /o [1] to [4], wherein the fatty acid that constitutes ingredient A
is oleic acid, myristic acid or 2-ethylhexanoic acid.
[6] The emulsified composition for dilution described in any of [1] to [5], wherein the ester of ingredient A is ethyl oleate, octyldodecyl myristate or cetyl 2-ethylhexanoate.
[7] The emulsified composition for dilution described in any of [1] to [6], wherein the hydroxy fatty acid triglyceride that constitutes the ingredient B nonionic surfactant is castor oil or hardened castor oil.
[8] A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with 1 part by volume of the emulsified composition for dilution described in any of [1] to [7].
[9] A cancer vaccine composition comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10 C, at 30 to 80% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C, at 0 to 20% by weight; and E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;

ak 02595063 2007-07-17 wherein the composition is a 14/0 emulsion.
[10] The cancer vaccine composition described in [9], comprising ingredient A at 40 to 60% by weight;
ingredient B at 1.0 to 5.0% by weight;
ingredient C at 5.0 to 10.0% by weight; and ingredient E at 30 to 50% by weight.
[11] A specific CTL inducer comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10 C, at 30 to 80% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C, at 0 to 20% by weight; and E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;
wherein the composition is a WO emulsion.
[12] The specific CTL inducer described in [11], comprising ingredient A at 40 to 60% by weight;
ingredient B at 1.0 to 5.0% by weight;
ingredient C at 5.0 to 10.0% by weight; and ingredient E at 30 to 50% by weight.
[13] A kit for freshly preparing a cancer vaccine composition or specific CTL inducer, comprising a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, and the emulsified composition for dilution for diluting the water phase, described in any of [1] to [7].
[14] A commercial package comprising a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, the emulsified composition for dilution described in any of [1] to [7], and a printed matter bearing the statement that a WO emulsion obtained by diluting the water phase with an emulsified composition for dilution can be used, or should be used, for the treatment or prevention of cancer.
Specific aspects of the invention include:
1) An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
2) An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dither thereof, comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;

(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm;
3) An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, consisting essentially of:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
7a =

wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm;
4) An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, consisting of:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm;
5) The emulsified composition of aspects 2) to 4) in which the ester of (A) constitutes 60-80% by weight;
6) The emulsified composition of aspects 2) to 5) in which the nonionic surfactant of (B) constitutes 1-10% by weight;
7b 7) The emulsified composition of aspects 2) to 6) in which the emulsifier of (C) constitutes 5-15% by weight;
8) The emulsified composition of aspects 2) to 6) in which the emulsifier of (C) constitutes 1-20% by weight;
9) The emulsified composition of aspects 2) to 8) wherein the fatty acid of (A) is oleic acid, myristic acid or 2-ethylhexanoic acid;
10) The emulsified composition of aspects 2) to 8) wherein the ester of (A)is ethyl oleate, octyldodecyl myristate or cetyl 2-ethylhexanoate;
11) The emulsified composition of aspects 2) to 8) wherein the ester of (A) is ethyl oleate, octyldodecyl myristate or a combination thereof;
12) The emulsified composition of aspects 2) to 11) wherein the hydroxy fatty acid triglyceride of (B) is castor oil or hardened castor oil;
13) The emulsified composition of aspects 2) to 11), wherein the hydroxy fatty acid triglyceride of (B) is hardened castor oil adduct with 20 mol of ethylene oxide;
14) The emulsified composition of aspects 2) to 13) wherein the emulsifier of (C) is glycerin monooleate, sorbitan monooleate, or a combination thereof;
15) The emulsified composition of aspects 2) to 4), wherein the nonionic surfactant of (B) consists of a hardened castor oil adduct with 10 to 20 mol of ethylene oxide;
7c 16) A cancer vaccine composition comprising:
(A) 30 to 80% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 10 to 60% by weight of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof;
wherein the composition is a WO emulsion;
17) The cancer vaccine composition of aspect 16), comprising:
40 to 60% by weight of the ester of (A);
0.5 to 20% by weight of the nonionic surfactant of (B);
5 to 10% by weight of the emulsifier of (C); and to 50% by weight of the water phase of (D);
7d ak 02595063 2012-09-24 =
18) The cancer vaccine composition of aspect 16) or 17) wherein the ester of (A) is ethyl oleate, octyldodecyl myristate or a combination thereof;
19) The cancer vaccine composition of aspects 16) to 18), wherein the hydroxy fatty acid triglyceride of (B) is hardened castor oil adduct with 20 mol of ethylene oxide;
20) The cancer vaccine composition of aspects 16) to 19) wherein the emulsifier of (C) is glycerin monooleate, sorbitan monooleate, or a combination thereof;
21) A cancer vaccine composition which is a WO
emulsion obtained by diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of the emulsified composition of aspects 1) to 15);
22) A specific cytotoxic T cell inducer comprising:
(A) 30 to 80% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and 7e . .
(D) 10 to 60% by weight of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof;
wherein the composition is a WO emulsion;
23) The specific cytotoxic T cell inducer of aspect 22), comprising:
40 to 60% by weight of the ester of (A);
0.5 to 20% by weight of the nonionic surfactant of (B);
5 to 10% by weight of the emulsifier of (C); and 30 to 50% by weight of the water phase of (D);
24) A specific cytotoxic T cell inducer which is a WO emulsion obtained by diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with 1 part by volume of an emulsified composition of aspects 1) to 15);
25) A kit for freshly preparing a cancer vaccine composition, comprising a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, and an emulsified composition for diluting the water phase, wherein the emulsified composition comprises:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
7f =

(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
26) A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of an emulsified composition comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10 C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(c) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C; and (D) 5 to 20% by weight of water;
and 7g 27) A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of the emulsified composition of aspects 1) to 15).
7h Brief Description of the Drawings Figure 1 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising the TERT
peptide.
Figure 2 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising the MAGE-1 peptide.
Figure 3 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising the PSA
peptide.
Figure 4 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising the PSA
peptide.
Figure 5 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising the CEA
peptide.
Figure 6 is a graph showing the results of specific CTL
induction using cancer vaccine compositions comprising various cancer antigen peptides.
Figure 7 shows the particle size distribution of emulsified composition for dilution 8.
Figure 8 shows the particle size distribution of emulsified composition for dilution 29.
Figure 9 is a graph showing the results of specific CTL
induction to each peptide using cancer vaccine compositions comprising a mixture of two kinds of cancer antigen peptide.
Best Mode for Embodying the Invention The emulsified composition for dilution of the present invention is hereinafter described in detail.
The "emulsified composition for dilution" of the present invention refers to a composition used to dilute a cancer antigen peptide or a dimer thereof. The "cancer vaccine composition" of the present invention refers to a composition obtained by diluting a cancer antigen peptide or a dimer thereof ak 02595063 2007-07-17 with the emulsified composition for dilution of the present invention.
The emulsified composition for dilution of the present invention is an emulsion pre-emulsified into the w/o type. The emulsified composition for dilution of the present invention is a composition for diluting a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof;
by so diluting the water phase, a cancer vaccine composition that stimulates CTL induction specific for each cancer antigen lo peptide can be prepared.
In the emulsified composition for dilution of the present invention, ingredient A is an ester of a fatty acid and an alcohol, preferably an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10 C.
The ester of a fatty acid and an alcohol, used as ingredient A, may be chosen from among those that have a solidification point of not more than 10 C. If the solidification point of ingredient A exceeds 10 C, it is feared that the stability, particularly the stability at low temperature, of the emulsified composition for dilution decreases, and this is therefore undesirable.
As examples of the fatty acid having 8 to 22 carbon atoms, saturated or unsaturated fatty acids having 8 to 22 carbon atoms can be mentioned; specifically, caprylic acid, 2-ethylhexanoic acid, nonanoic acid, capric acid, undecanoic acid, lauric acid, tridecanoic acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, isopalmitic acid, palmitoleic acid, isostearic acid, stearic acid, oleic acid, linoleic acid, nervonic acid and the like can be mentioned. As examples of the alcohol having 2 to 24 carbon atoms, alkanols having 2 to 24 carbon atoms and alkenols having 2 to 24 carbon atoms can be mentioned; specifically, alcohols such as ethanol, propanol, isopropanol, ethylene glycol, butanol, hexanol, octanol, 2-ethylhexanol, decanol, dodecanol, myristyl alcohol, cetyl ak 02595063 2007-07-17 alcohol, isocetyl alcohol (2-hexyldecanol), isostearyl alcohol, oleyl alcohol, icosenol, docosenol, tetracosenol, and 2-octyldodecanol and the like can be mentioned.
As examples of the ingredient A used in the present invention, specifically, cetyl 2-ethylhexanoate, hexyl laurate, butyl myristate, isopropyl myristate, isocetyl myristate, octyldodecyl myristate, 2-ethylhexyl palmitate, isostearyl palmitate, isopropyl isostearate, isocetyl isostearate, 2-ethylhexyl stearate, ethyl oleate, decyl oleate, oleyl oleate, octyldodecyl oleate, ethyl linoleate, isopropyl linoleate and the like can be mentioned.
The ingredient A used in the present invention may be synthesized as an ester, and may be extracted/purified from a natural oil or fat. As examples of the naturally derived ester oil, jojoba oil, orange roughy oil and the like can be mentioned.
These esters are generally commercially available, from among which one suitable for pharmaceutical use may be chosen according to the purpose.
The ingredient A used in the present invention is preferably an oleic acid ester, a myristic acid ester or a 2-ethylhexanoeic acid ester, more preferably ethyl oleate, octyldodecyl myristate, or cetyl 2-ethylhexanoate, still more preferably ethyl oleate.
In the emulsified composition for dilution of the present invention, the content of ingredient A is 50 to 90% by weight, preferably 55 to 85% by weight, more preferably 60 to 80% by weight. If the content of ingredient A is less than 50% by weight, the finished cancer vaccine composition obtained by diluting a cancer antigen peptide possibly becomes unstable, and this is therefore undesirable.
In the emulsified composition for dilution of the present invention, the ingredient B is a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide.
The hydroxy fatty acid triglyceride adduct with ethylene ak 02595063 2007-07-17 oxide is a surfactant widely used for emulsification, solubilization and the like, and 5 to 100 mol of ethylene oxide adducts are commercially available. A surfactant consisting of less than 5 mol of ethylene oxide adduct has a low surfactant activity such that an emulsified composition for dilution showing a good emulsified state cannot be formed, and this is therefore undesirable. Because a surfactant consisting of more than 20 mol of ethylene oxide adduct is highly hydrophilic, not only it is feared that the emulsification stability decreases due to aggregation of water phase particles and the like in the cancer vaccine composition obtained by diluting the emulsified composition, but also the CTL induction activity for the cancer vaccine composition can decrease, and this is therefore undesirable.
The nonionic surfactant used as the ingredient B is preferably constituted by a castor oil or hardened castor oil adduct with 5 to 20 mol of ethylene oxide. By using such a nonionic surfactant, an emulsified composition for dilution of excellent stability can be obtained, and, furthermore, a cancer vaccine composition that exhibits excellent stability and high CTL induction activity when a cancer antigen peptide is diluted with the emulsified composition for dilution can be prepared. By using a nonionic surfactant constituted by a castor oil or hardened castor oil adduct with 5 to 20 mol of ethylene oxide, a cancer vaccine composition of excellent safety to the administration site can be finally prepared. Of these, preferable as the ingredient B of the present invention is a hardened castor oil adduct with 10 to 20 mol of ethylene oxide.
Furthermore, in the present invention, it is most preferable to use, out of these, a hardened castor oil adduct with 10 mol of ethylene oxide.
In the emulsified composition for dilution of the present invention, the content of ingredient B is 0.5 to 20% by weight, preferably 1 to 15% by weight, more preferably 1 to 10% by weight. If the content of ingredient B is less than 0.5% by ak 02595063 2007-07-17 weight, the surfactant activity decreases in excess and, as a result, it is possible that no stable emulsified composition for dilution is obtained, and this is therefore undesirable.
Conversely, if the content exceeds 20% by weight, not only phase conversion occurs during dilution of the cancer antigen peptide, which hampers the final obtainment of a good cancer vaccine composition, but also it is feared that the safety of the cancer vaccine composition to the administration site decreases, and this is therefore again undesirable.
/o The ingredient C optionally contained in the emulsified composition for dilution of the present invention is an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40 C.
In the present invention, in addition to the above-described ingredient B, by containing ingredient C, a cancer vaccine composition that exhibits a better emulsified state and has excellent stability when used to dilute a cancer antigen peptide can be prepared and, as a result, a cancer vaccine composition that exhibits excellent CTL induction activity in diversified kinds of peptides can be obtained.
As examples of the polyhydric alcohol that constitutes the ingredient C of the present invention, glycerin, diglycerin, sorbitan, sorbitol, sorbide, mannitan, mannitol, sucrose and the like can be mentioned. As examples of the fatty acid that constitutes the ingredient C, lauric acid, myristic acid, isostearic acid, oleic acid, linoleic acid and the like can be mentioned. As the ingredient C of the present invention, one being liquid at 40 C may be chosen from among these partial esters of a polyhydric alcohol and a fatty acid.
As specific suitable examples of ingredient C, glycerin monooleate, glycerin dioleate, diglycerin monooleate, diglycerin dioleate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, mixtures thereof and the like can be mentioned. Particularly suitable ones are glycerin monooleate, glycerin dioleate, sorbitan monooleate, sorbitan sesquioleate, ak 02595063 2007-07-17 sorbitan dioleate, and mixtures thereof. These are generally commercially available, from among which those suitable for pharmaceutical use can be chosen.
In the emulsified composition for dilution of the present invention, the content of ingredient C is chosen from the range of 0 to 20% by weight. In particular, the range of 1 to 20% by weight is preferable, and the range of 5 to 15% by weight is more preferable. At this time, if the content exceeds 20% by weight, not only the viscosity for the emulsified composition for dilution increases so that a good cancer vaccine composition cannot be obtained when the cancer antigen peptide of the present invention is diluted, but also it is feared that the safety of the cancer vaccine composition to the administration site decreases, and this is therefore undesirable. If the content of ingredient C is not less than 1% by weight, a sufficient additive effect is exhibited, and this is therefore preferable.
The ingredient D that constitutes the emulsified composition for dilution of the present invention is a water phase for forming an emulsion. The ingredient D of the present invention may be chosen from among aqueous ingredients in common use in pharmaceuticals; for example, purified water, water for injection, phosphate-buffered solution, physiological saline, phosphate-buffered saline and the like can be mentioned. The content of ingredient D in the emulsified composition for dilution of the present invention is 5 to 20% by weight, preferably 8 to 16% by weight.
In the emulsified composition for dilution of the present invention, in addition to the above-described ingredients, an antioxidant, a stabilizer and the like can also be added, as long as the emulsion stability is not affected.
As examples of the antioxidant, tocopherols such as a-tocopherol and o-tocopherol, gallic acid esters, dibutylhydroxytoluene and the like can be mentioned.
As the stabilizer, alcohols such as glycerin, propylene ak 02595063 2007-07-17 glycol, 1,3-butylene glycol, polyethylene glycol and the like can be mentioned.
The emulsified composition for dilution of the present invention can be produced by an ordinary method of producing an emulsified composition adopted as appropriate. Usually, a method is chosen in which ingredient A, ingredient B and ingredient C
are previously mixed, ingredient D is gradually added while stirring the mixture, and the mixture is finally stirred and emulsified using an emulsifying apparatus such as a homogenizer.
/o The emulsified composition for dilution of the present invention is preferably obtained in the form of a WO emulsion having a very low viscosity and a fine particle diameter.
The average particle diameter of the dispersion phase of the emulsified composition for dilution of the present invention is preferably not more than 1000 rim, more preferably not more than 500 rim, still more preferably 50 to 500 rim, particularly preferably 50 to 300 rim.
In the present invention, the average particle diameter of the dispersion phase of the emulsified composition for dilution is expressed as the mean of the particle diameters of all particles (dispersion phase) measured by the dynamic light scattering method. Specifically, particle diameters can be measured by applying a sample obtained by diluting as appropriate an emulsified composition as the subject of measurement with ingredient A to, for example, ZETASIZER NANO-S
manufactured by MALVERN INSTRUMENTS Company and the like.
If the average particle diameter of the dispersion phase exceeds 1000 rim, not only the stability for the emulsified composition for dilution decreases, but also it is feared that the homogeneity, stability, and CTL induction activity of the cancer vaccine composition finally obtained by diluting a water phase comprising a cancer antigen peptide decrease, and this is therefore undesirable. Provided that the average particle diameter of the dispersion phase is 50 to 300 rim, the emulsified composition can also be filter-sterilized in the state of a WO

ak 02595063 2007-07-17 emulsion. The filter used for the filter sterilization may be chosen as appropriate to the filtration of oily liquid.
Specifically, a hydrophobic membrane filter having a pore diameter of 0.2 'Am (made of polytetrafluoroethylene) and the like can be mentioned.
The emulsified composition for dilution of the present invention is used to obtain a cancer vaccine or specific CTL
inducer that stimulates CTL induction specific for each antigen when combined with a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof. In so preparing a cancer vaccine composition or specific CTL inducer, 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof may be diluted with 1 part by volume of an emulsified composition for dilution. At this time, the cancer antigen peptide or dimer thereof may be dissolved or suspended in the water phase.
The emulsified composition for dilution of the present invention is a WO emulsion having water particles finely dispersed therein, and is of very low viscosity. Therefore, when a peptide-containing water phase is diluted with this emulsified composition for dilution, a stable 11/0 emulsion can be easily obtained. The emulsified composition of the present invention is a stable WO emulsion per se. The cancer vaccine composition or specific CTL inducer obtained by diluting a water phase comprising a cancer antigen peptide with the emulsified composition of the present invention as described above is also a stable 1,1/0 emulsion.
Therefore, as the stirring methods for diluting a water phase comprising a cancer antigen peptide with the emulsified composition for dilution of the present invention, an ordinary emulsifying apparatus such as a homogenizer or homomixer may be used, and a simple stirring apparatus not in common use for emulsification, for example, a shikenkan mixer and the like may be used. The above-described dilution can also be performed by the syringe connection method, which peLmits simple operation in ak 02595063 2007-07-17 the laboratory. Hence, the dilution can also be freshly prepared just before administration according to the intended use.
Preferably, by adding an emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof in a ratio by volume of 1:0.25 to 1:1, and then stirring the mixture using a shikenkan mixer for about 30 seconds to 3 minutes according to stirring speed, a stable and good cancer vaccine composition or specific CTL inducer can be obtained. At this time, it is preferable that while the emulsified composition for dilution is stirred using the shikenkan mixer, the water phase comprising the cancer antigen peptide is gradually added, and after the entire quantity to be added has been added, the mixture is further stirred for not less than 30 seconds.
The cancer vaccine composition or specific CTL inducer in the present invention is obtained by diluting and mixing a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with the emulsified composition for dilution of the present invention as described above, and, as described above, occurs in the form of a stable 14/0 emulsion.
Peptides are generally susceptible to heat, and are often difficult to keep stable in water for a long time. As described above, in the present invention, because the dilution can be prepared before use by a simple method, even when using a peptide of relatively low stability to heat and in water, the degradation and aggregation of the peptide during emulsifying operation and storage are reduced. Hence, because undesirable deterioration of a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof is avoided by using the emulsified composition for dilution of the present invention, it becomes possible to prepare a cancer vaccine composition or specific CTL
inducer that stably retains various peptides (including dimers thereof), irrespective of the kind and properties thereof.
In the present invention, the cancer antigen peptide is a cancer antigen peptide having 8 to 12 amino acids or a dimer ak 02595063 2007-07-17 thereof, presented to MHC class I antigen, and comprising a peptide recognized as an antigen by CTL.
In the present invention, the cancer antigen peptide having 8 to 12 amino acids can be chosen from among commonly known ones. For example, partial peptides derived from gp100 and MART-1, which are melanocyte tissue specific proteins, and melanosome proteins such as tyrosinase, can be mentioned. As other cancer antigen peptides, partial peptides derived from cancer markers such as CEA, PSA, and HER2/neu; partial peptides derived from cancer.testis antigens such as MAGE-1, MAGE-2, MAGE-3 and NY-ES0-1; partial peptides derived from epithelial cancer cell protein such as MUC-1, SART-1, and SART-3, and the like can be mentioned. Furthermore, partial peptides derived from TERT, whose expression is increased in cancer, WT1-derived partial peptides, Survivin-2B-derived partial peptides and the like can also be mentioned as suitable cancer antigen peptides.
These may be natural substances or modifications thereof wherein some amino acids have been modified, as long as they do not interfere with therapeutically effective specific CTL
induction for each cancer antigen in the finally obtained cancer vaccine composition or specific CTL inducer.
These cancer antigen peptides may be contained in the cancer vaccine composition or specific CTL inducer not only singly, but also in combination of two or more kinds.
These cancer antigen peptides can be obtained by solid phase synthesis based on the Fmox method and the like, and other commonly known methods.
As specific examples of the amino acid sequence of each cancer antigen peptide, the following can be mentioned. Cancer antigen peptides having the amino acid sequences shown below are commonly known.
(1) For gp100-derived peptides, KTWGQYWQV (SEQ ID NO:1), AMLGTHTMEV (SEQ ID NO: 2), MLGTHTMEV (SEQ ID NO: 3), ITDQVPFSV
(SEQ ID NO:4), YLEPGPVTA (SEQ ID NO:5), LLDGTATLRL (SEQ ID NO:6), VLYRYGSFSV (SEQ ID NO:7), SLADTNSLAV (SEQ ID NO:8), RLMKQDFSV

ak 02595063 2007-07-17 (SEQ ID NO:9), RLPRIFCSC (SEQ ID NO:10), VYFFLPDHL (SEQ ID
NO:11) and the like;
(2) for MART-1-derived peptides, AAGIGILTV (SEQ ID NO:12), EAAGIGILTV (SEQ ID NO:13), ILTVILGVL (SEQ ID NO:14) and the like;
(3) for tyrosinase-derived peptides, MLLAVLYCL (SEQ ID NO:15), YMDGTMSQV (SEQ ID NO:16), AFLPWHRLF (SEQ ID NO:17), AFLPWHRLFL
(SEQ ID NO:18) and the like;
(4) for CEA-derived peptides, YLSGANLNL (SEQ ID NO:19), IMIGVLVGV (SEQ ID NO:20), LLTFWNPPT (SEQ ID NO:21), QYSWFVNGTF
(SEQ ID NO:22), TYACFVSNL (SEQ ID NO:23) and the like;
(5) for PSA-derived peptides, FLTPKKLQCV (SEQ ID NO:24), VSHSFPHPLY (SEQ ID NO:25), VISNDVCAQV (SEQ ID NO:26), CYASGWGSI
(SEQ ID NO:27) and the like;
(6) for MUC-1-derived peptides, STAPPVHNV (SEQ ID NO:28) and the like;
(7) for HER2/neu-derived peptides, QIISAVVGIL (SEQ ID NO:29), QLFEDNYAL (SEQ ID NO:30), KIFGSLAFL (SEQ ID NO:31), CLTSVQLV
(SEQ ID NO:32), VMAGVGSPYV (SEQ ID NO:33), RLLQETELV (SEQ ID
NO:34), PYVSRLLGI (SEQ ID NO:35), TYLPTNASL (SEQ ID NO:36) and the like;
(8) for MAGE-1-derived peptides, NYKHCFPEI (SEQ ID NO:37) and the like;
(9) for MAGE-3-derived peptides, FLWGPRALV (SEQ ID NO:38), KVAELVHFL (SEQ ID NO:39), IMPKAGLLI (SEQ ID NO:40), TFPDLESEF
(SEQ ID NO:41) and the like;
(10) for NY-ES0-1-derived peptides, SLLMWITQC (SEQ ID NO:42), SLLMWITQCFL (SEQ ID NO:43), QLSLLMWIT (SEQ ID NO:44) and the like;
(11) for SART-1-derived peptides, EYRGFTQDF (SEQ ID NO:45) and the like;
(12) for SART-3-derived peptides, VYDYNCHVDL (SEQ ID NO:46) and the like;
(13) for TERT-derived peptides, ILAKFLHWL (SEQ ID NO:47), VYAETKHFL (SEQ ID NO: 48), VYGFVRACL (SEQ ID NO:49).and the like;

ak 02595063 2007-07-17 (14) for WT1-derived peptides, RMFPNAPYL (SEQ ID NO:50), CMTWNQMNL (SEQ ID NO:51), RWPSCQKKF (SEQ ID NO:52) and the like;
(15) for Survivin-2B-derived peptides, AYACNTSTL (SEQ ID NO:53) and the like:
In this description, the left end of each of the above-described peptides indicates the N terminus thereof, and the individual amino acid symbols show the following amino acid residues, respectively.
A: Alanine residue G: Glycine residue M: Methionine residue S: Serine residue C: Cysteine residue H: Histidine residue N: Asparagine residue T: Threonine residue D: Aspartic acid residue I: Isoleucine residue P: Proline residue V: Valine residue E: Glutamic acid residue K: Lysine residue Q: Glutamine residue W: Tryptophan residue F: Phenylalanine residue L: Leucine residue R: Arginine residue Y: Tyrosine residue These cancer antigen peptides are partial peptides of cancer antigen proteins, and some of them have cysteine at the N
terminus of the amino acid sequence thereof. Such a cancer antigen peptide is likely to dimerize in water, and part or almost all of its content often has dimerized at the time of administration. In the present invention, even if a peptide having 8 to 12 amino acids dimerizes as described above, it ak 02595063 2007-07-17 exhibits similar CTL induction activity; therefore, a cancer antigen peptide can be chosen from among cancer antigen peptides having 8 to 12 amino acids or a dimer thereof according to the intended use. To efficiently induce CTL in vivo, the cancer antigen peptide in the present invention is preferably an epitope sequence restricted by HLA-A2402 (also simply referred to as HLA-A24) or HLA-A0201 (also simply referred to as HLA-A2) out of the cancer antigen peptides having 8 to 12 amino acids.
By using such a cancer antigen peptide, an effective cancer vaccine composition that eventually induces and activates cytotoxic T cells in vivo can be prepared.
The concentration of the cancer antigen peptide (including a dimer thereof; the same applies below) in the water phase when mixed with the emulsified composition for dilution of the /5 present invention may be chosen according to the kind of peptide used so that the content in the finally obtained cancer vaccine composition will fall in the appropriate range for activating CTL induction. The cancer vaccine composition or specific CTL
inducer of the present invention (hereinafter also simply referred to as cancer vaccine composition) can be kept stable irrespective of the kind and properties of the peptide by using an emulsified composition for dilution, and the peptide concentration to be contained can be set in a broad range.
Specifically, although it varies depending on the route of administration and methods of administration, usually, the peptide concentration in the finally obtained cancer vaccine composition is 0.01 to 100 mg/mL.
Regarding the route of administration of the cancer vaccine composition of the present invention, a method of 50 administration in common use may be chosen, as long as activation of CTL induction specific for the cancer antigen peptide used is possible. As examples of the route of administration, subcutaneous, intradermal, intramuscular and the like can be mentioned.
The dose of the cancer antigen peptide can be adjusted as appropriate according to the disease to be treated, the patient's symptoms, age, body weight, sex and the like, and is 0.001 to 100 mg, more preferably 0.01 to 10 mg; this dose is preferably administered once per several days to several months.
The cancer vaccine composition of the present invention is a WO emulsion. The cancer vaccine composition of the present invention is a WO emulsion comprising ingredient A at 30 to 80%
by weight, ingredient B at 0.5 to 20% by weight, ingredient C at 0 to 20% by weight, and ingredient E at 10 to 60% by weight, /o preferably comprising ingredient A at 40 to 60% by weight, ingredient B at 1.0 to 5.0% by weight, ingredient C at 5.0 to 10.0% by weight, and ingredient E at 30 to 50% by weight.
Considering the preservation and administration using a syringe for injection, the cancer vaccine composition of the present invention is preferably liquid at 5 C, and preferably has a viscosity at 25 C of not more than 300 mPa.s, more preferably not more than 200 mPa.s.
In the water phase that is the ingredient E of the present invention, a stabilizer, a solvent, a solubilizer, a suspending agent, a diluent, a buffering agent, a tonicity agent, an acidifying agent, an alkalizing agent and the like may be contained according to the properties of the cancer antigen peptide, as long as they do not influence the stability of the finally obtained cancer vaccine composition. Therefore, when a water phase comprising an antigen peptide is diluted with an emulsified composition for dilution, each of the above-described excipients may be chosen as appropriate according to the properties of the antigen peptide.
The cancer vaccine composition of the present invention stimulates CTL induction specific for the cancer antigen peptide contained, and attacks cancer cells.
CTL induction activity can be confirmed by counting the number of CTLs by the HLA tetramer method (Int. J. Cancer: 100, 565-570 (2002)) or limited dilution method (Nat. Med.: 4, 321-327 (1998)). Alternatively, for example, HLA-A24-restricted CTL

induction activity can be confirmed by using the HLA-A24 model mouse described in the pamphlet for International Patent Publication No. 02/47474 and Int. J. Cancer: 100, 565-570 (2002), and the like.
The cancer vaccine composition of the present invention has the capability of inducing specific CTL according to the cancer antigen peptide contained; the CTL induced exhibits cytotoxic action and anticancer action via lymphokine production.
Therefore, the cancer vaccine composition of the present invention can be used as a cancer immunotherapy preparation for the treatment or prevention of cancer.
Examples The present invention is hereinafter described in more detail by means of the following Examples, which, however, are not to be construed as limiting the scope of the invention.
<Preparation of emulsified composition for dilution>
[Example 1]
Ethyl oleate (a supply conforming to the Japanese Pharmaceutical Excipients) as ingredient A, polyoxyethylene (10) hardened castor oil (a supply conforming to the Japanese Pharmaceutical Excipients; 10 mol of ethylene oxide adduct) as ingredient B, and sorbitan sesquioleate (a supply conforming to the Japanese Pharmacopoeia) as ingredient C were mixed in the amounts shown in Table 1, respectively. Next, while stirring this mixture, water for injection (a supply conforming to the Japanese Pharmacopoeia) as ingredient D was gradually added in the amounts shown in Table 1. Emulsification was performed by stirring using CLEARMIX 1.5S (manufactured by M-TECHNIQUE Co., Ltd.) at 10,000 rpm for 5 minutes at room temperature. Thereby, 50 an emulsified composition for dilution 1 was obtained. When this emulsified composition was allowed to stand at room temperature for 24 hours after preparation, no change in the appearance was observed.
[Examples 2 to 35]
In the same manner as Example 1, the ingredients other ak 02595063 2007-07-17 than ingredient D were previously mixed. While stirring this mixture, ingredient D was gradually added and emulsification was performed. In all cases, emulsification was performed by stirring using CLEARMIX 1.5S (manufactured by M-TECHNIQUE Co., Ltd.) at 10,000 rpm for 5 minutes at room temperature. As ingredient D, water for injection, 10 mM phosphate-buffered solution (pH 7.4), and 10 mM phosphate-buffered saline (pH 7.4) were used respectively according to Tables 1 to 7. Each ingredient shown in Tables 1 to 7 were supplies conforming to the Japanese Pharmacopoeia, the Japanese Pharmaceutical Excipients, or Japanese Standards of Cosmetic Ingredients.
Thereby, emulsified compositions 2 to 35 were obtained. When the emulsified compositions for dilution 2 to 35 obtained were allowed to stand at room temperature for 24 hours after preparation, and examined for appearance change; no change such as separation was observed in any of the emulsified compositions.
[Comparative Examples 1 to 25]
In the same manner as Example 1, ethyl oleate (a supply conforming to the Japanese Pharmaceutical Excipients), the various polyoxyethylene hardened castor oils shown in Tables 8 to 12 (supplies conforming to the Japanese Pharmaceutical Excipients), and sorbitan sesquioleate (a supply conforming to the Japanese Pharmacopoeia) were mixed to obtain the amounts shown in Tables 8 to 12, respectively. Polyoxyethylene (40) hardened castor oil, polyoxyethylene (60) hardened castor oil and the like were mixed in a state molten by heating at 50 C.
Because the polyoxyethylene (160) polyoxypropylene (30) glycol used to prepare an emulsified composition 46 (Comparative Example 11) is not easy to mix, it was previously dissolved in a water phase and mixed at the time of emulsification. Next, while stirring this, water for injection, 10 mM phosphate-buffered solution (pH 7.4), and 10 mM phosphate-buffered saline (pH 7.4) were gradually added according to Tables 8 to 12, respectively.
Emulsification was performed by stirring using CLEARMIX 1.5S
(manufactured by M-TECHNIQUE Co., Ltd.) at 10,000 rpm for 5 minutes at room temperature. Thereby, emulsified compositions for dilution 36 to 60 were obtained. Each ingredient shown in the Tables was supplies conforming to the Japanese Pharmacopoeia, the Japanese Pharmaceutical Excipients, or Japanese Standards of Cosmetic Ingredients. For the ingredients not listed in any of these compendia, supplies of pharmaceutical grade were used.
When each emulsified composition obtained was allowed to stand for 24 hours after preparation, no change such as separation was observed in the emulsified compositions 36 to 39, 56 and 57, but /0 separation of the oil phase and the water phase (including creaming) was observed in the emulsified compositions 40 to 55 and 58 to 60.
Table 1 Example Emulsified composition 1 2 3 4 5 number Ethyl oleate 70.0 70.0 70.0 70.0 Cetyl 2-ethylhexanoate 70.0 Polyoxyethylene (10) 3.0 3.0 3.0 3.0 3.0 hardened castor oil Sorbitan sesquioleate 12.0 - 12.0 Sorbitan monooleate 12.0 12.0 12.0 Water for injection 15.0 15.0 15.0 Phosphate-buffered saline 15.0 15.0 (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 2 _ Example Emulsified composition 6 7 8 9 10 number Ethyl oleate 70.0 70.0 70.0 70.0 70.0 Polyoxyethylene (5) - 3.0 - - -hardened castor oil Polyoxyethylene (10) 3.0 - 3.0 - -hardened castor oil Polyoxyethylene (10) - - - 3.0 -castor oil Polyoxyethylene (20) - - - - 3.0 hardened castor oil Sorbitan sesquioleate - 6.0 6.0 6.0 6.0 Glycerin monooleate 12.0 6.0 6.0 6.0 6.0 Phosphate-buffered 15.0 15.0 15.0 15.0 15.0 solution (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 3 Example Emulsified composition 11 12 13 14 15 number Ethyl oleate 70.0 - - - -Cetyl 2-ethylhexanoate - 70.0 - - -Octyldodecyl myristate - - 70.0 - -2-ethylhexyl palmitate - - - 70.0 -Oleyl oleate - - - - 70.0 Polyoxyethylene (10) 2.0 3.0 3.0 - -hardened castor oil Polyoxyethylene (20) 1.0 - - 3.0 3.0 hardened castor oil Sorbitan sesquioleate 12.0 6.0 6.0 6.0 6.0 Glycerin monooleate - 6.0 6.0 6.0 6.0 Water for injection 15.0 15.0 15.0 15.0 15.0 Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 4 Example Emulsified composition 16 17 18 19 20 number Cetyl 2-ethylhexanoate 70.0 70.0 -Ethyl oleate 70.0 70.0 Octyldodecyl myristate 70.0 Polyoxyethylene (10) 3.0 - 2.0 5.0 3.0 hardened castor oil Polyoxyethylene (20) 3.0 1.0 hardened castor oil Sorbitan sesquioleate 6.0 12.0 6.0 6.0 11.0 Glycerin monooleate 5.0 - 5.0 5.0 Glycerin 1.0 - 1.0 1.0 1.0 Phosphate-buffered 15.0 15.0 15.0 15.0 15.0 solution (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 5 Example Emulsified composition 21 22 23 24 25 number Ethyl oleate 70.0 - 70.0 70.0 Cetyl 2-ethylhexanoate 70.0 -Octyldodecyl myristate 70.0 -Polyoxyethylene (10) 15.0 15.0 15.0 15.0 15.0 hardened castor oil Water for injection 15.0 15.0 15.0 -Phosphate-buffered water 15.0 15.0 (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 6 Example Emulsified composition 26 27 28 29 30 number Cetyl 2-ethylhexanoate 75.0 75.0 -Ethyl oleate 75.0 75.0 75.0 Polyoxyethylene (5) 3.5 hardened castor oil Polyoxyethylene (10) 14.0 3.0 3.0 hardened castor oil Polyoxyethylene (20) 2.5 hardened castor oil Sorbitan sesquioleate 6.0 6.5 12.0 11.5 Glycerin monooleate 6.0 5.0 Glycerin 1.0 - 1.0 Phosphate-buffered water 10.0 10.0 10.0 10.0 10.0 (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 7 Example Emulsified composition 31 32 33 34 35 number Ethyl oleate 72.0 78.0 80.0 74.0 -Jojoba oil 70.0 Polyoxyethylene (10) 3.0 3.5 3.0 3.0 3.0 hardened castor oil Sorbitan sesquioleate 15.0 7.5 5.0 15.0 12.0 Glycerin 1.0 1.0 1.0 Phosphate-buffered water 10.0 10.0 12.0 7.0 15.0 (pH 7.4) Change in state after being allowed to stand at None None None None None room temperature for 24 hours Table 8 Comparative Example Emulsified composition 36 37 38 39 40 number Ethyl oleate 70.0 70.0 - 70.0 70.0 Cetyl 2-ethylhexanoate - - 70.0 - -Polyoxyethylene (30) - 3.0 - - -hardened castor oil Polyoxyethylene (40) 3.0 - 3.0 - -hardened castor oil Polyoxyethylene (60) _ _ _ 3.0 _ hardened castor oil Sorbitan sesquioleate 12.0 6.0 6.0 6.0 7.5 Glycerin monooleate - 6.0 6.0 6.0 7.5 Water for injection 15.0 15.0 15.0 15.0 15.0 Change in state after being allowed to stand at Separ None None None None room temperature for 24 ated hours Table 9 Comparative Example Emulsified composition 41 42 43 44 45 number .
Cetyl 2-ethylhexanoate 70.0 - - - -Diethyl sebacate - 70.0 - - -Purified soybean oil - - 70.0 - -Squalane - - - 70.0 -Light liquid paraffin - - - - 70.0 Polyoxyethylene (10) - 3.0 3.0 3.0 3.0 hardened castor oil Sorbitan sesquioleate 7.5 6.0 6.0 6.0 6.0 Glycerin monooleate 7.5 6.0 6.0 6.0 6.0 Water for injection 15.0 15.0 15.0 15.0 15.0 Change in state after Sligh being allowed to stand at Separ Separ Separ Separ tly room temperature for 24 ated ated ated ated separ hours ated Table 10 Comparative Example Emulsified 46 47 48 49 50 composition number Ethyl oleate 70.0 70.0 70.0 70.0 70.0 Polyoxyethylene (160) polyoxypropylene (30) 3.0 -glycol Polyoxyethylene (20) polyoxypropylene (20) 3.0 glycol Polyoxyethylene (6) 3.0 sorbitan monooleate Polyoxyethylene (6) 3.0 sorbitol tetraoleate Polyoxyethylene (30) 3.0 sorbitol tetraoleate Sorbitan sesquioleate 6.0 6.0 6.0 6.0 6.0 Glycerin monooleate 6.0 6.0 6.0 6.0 6.0 Phosphate-buffered water 15.0 15.0 15.0 15.0 15.0 (pH 7.4) Change in state after being allowed to stand at Separ Separ Separ Separ Separ room temperature for 24 ated ated ated ated ated hours Table 11 Comparative Example Emulsified 51 52 53 54 55 composition number Ethyl oleate 70.0 70.0 70.0 - 70.0 Cetyl 2-ethylhexanoate 70.0 -Polyoxyethylene (60) 15.0 15.0 -hardened castor oil Polysorbate 80 3.0 - 15.0 Castor oil 3.0 Sorbitan sesquioleate 6.0 6.0 Glycerin monooleate 6.0 6.0 Water for injection 15.0 15.0 15.0 15.0 15.0 Change in state after being allowed to stand at Separ Separ Separ Separ Separ room temperature for 24 ated ated ated ated ated hours Table 12 Comparative Example Emulsified composition 56 57 58 59 60 number Cetyl 2-ethylhexanoate 75.0 - - - -Ethyl oleate - 75.0 - -Squalane - 75.0 -Purified soybean oil - - 75.0 -Tri(caprylate/caprate) _ _ _ - 75.0 glycerin Polyoxyethylene (10) - - 3.0 3.0 3.0 hardened castor oil Polyoxyethylene (40) 3.0 - - - -hardened castor oil Polyoxyethylene (60) - 3.0 - -hardened castor oil Sorbitan sesquioleate 11.0 - 4.0 11.0 11.0 Glycerin monooleate 11.0 4.0 Glycerin 1.0 1.0 1.0 1.0 Phosphate-buffered water 10.0 10.0 10.0 10.0 10.0 (pH 7.4) , -Change in state after being allowed to stand at Separ Separ Separ None None room temperature for 24 ated ated ated hours [Test Example 1]
<Preparation of cancer vaccine compositions>
Of the emulsified compositions for dilution obtained in the Examples, those showing no apparent separation when allowed to stand for 24 hours after preparation were used to prepare cancer vaccine compositions comprising various cancer antigen peptides. The cancer antigen peptides used for the preparation /0 are shown in Table 13. All these peptides are HLA-A24-restricted.
ak 02595063 2007-07-17 Table 13 Name of Source Amino acid Amino acid sequence antigen protein positions peptide TERT Telomerase 324-332 VYAETKHFL (SEQ ID NO:48) MAGE-1 Melanoma 135-143 NYKHCFPEI (SEQ ID NO:37) antigen CEA Carcino- 652-660 TYACFVSNL (SEQ ID NO:23) embryonic antigen PSA Prostate- 152-160 CYASGWGSI (SEQ ID NO:27) specific antigen For TERT, MAGE-1, and CEA out of the cancer antigen peptides shown in Table 13, 1.2 mg of synthetic peptide was dissolved in 10.8 [IL of DMSO, after which the solution was diluted with 349.2 [LI, of water for injection, and the absence of precipitate was visually confirmed (DMSO concentration 3%). For PSA, 1.2 mg of synthetic peptide was diluted with water for injection to make 360 !IL, and the absence of precipitate was visually confirmed. Separately, the emulsified composition obtained in each Example was thoroughly mixed using a shikenkan mixer (Touch Mixer MT-51, manufactured by Yamato Scientific Co., Ltd.) (fully stirred and homogenized before use).
Next, 700 [IL of the emulsified composition was collected in cryogenic vial inner cap type of 5 mL capacity (manufactured by Sumitomo Bakelite Co., Ltd.) using a 1000 jjL Eppendorf pipette. Next, while stirring the tube using a shikenkan mixer, 300 jL of the above-described peptide-containing water phase was added drop by drop, and mixed. The stirring speed of the shikenkan mixer was set at the maximum level. After the peptide-containing water phase was added drop by drop, the mixture was further stirred using the shikenkan mixer for 2 minutes to yield a cancer vaccine composition.
In the experiments below, CTL induction activity was actually evaluated using prepared cancer vaccine compositions;
unless otherwise stated, the cancer vaccine compositions used for the evaluation were prepared according to the above-ak 02595063 2007-07-17 described method.
[Test Example 2]
<CTL induction with cancer vaccine composition comprising TERT
peptide>
The specific CTL induction potential of the cancer vaccine composition comprising the TERT peptide, prepared in Test Example 1, was evaluated using HLA-A24 transgenic mice (Int. J.
Cancer: 100, 565, 2002).
To prepare cancer vaccine compositions, emulsified compositions 7, 8, 37, 38, 39, and 45 were used. The cancer vaccine compositions prepared were given the same numbers as the emulsified compositions. In the evaluation, separately from Test Example 1, groups receiving an emulsion comprising the TERT
peptide, prepared using incomplete Freund's adjuvant (IFA, purchased from Wako Pure Chemical Industries, Ltd.), or the peptide water phase alone, as the dosing liquid, were established, and compared with groups receiving each cancer vaccine composition as the dosing liquid (matched to ensure that all dosing groups would receive the same dose of peptide). 200 III, of each dosing liquid (dose of each peptide 200 ilg) was subcutaneously administered to the tail root of each HLA-A24/Kb transgenic mouse. Three mice were used for each group. Seven to eight days after administration, the spleen was extirpated and splenocytes were prepared. Some of the splenocytes were pulsed with 100 pg/mL peptide for 1 hour. "Pulse" refers to adding a peptide to splenocytes to bind the antigen peptide to HLA on the cell surface. The splenocytes not pulsed with the peptide were sown to a 24-well plate at 7 x 106 cells/well, and the above splenocytes pulsed with the peptide were further added at 7 x 105 50 cells/well and cultured. The culture broth comprised an RPMI1640 medium supplemented with 10% FCS, 10 mM HEPES, 20 mM L-glutamine, 1 mM sodium pyruvate, 1 mM MEN non-essential amino acids, 1% MEN
vitamin, and 55 'AM 2-mercaptoethanol, and the cells were cultured for 5 to 6 days. The CTL activity specific for the peptide administered in the cultured splenocytes was measured by 51Cr release assay (J. Immunol.: 159, 4753, 1997). The target cells used were cells of the cell line EL4-A2402/Kb prepared by transferring a gene to mouse lymphoma-derived cell line EL-4 cells (ATCC line number TIB-39) so that the HLA-A24 and H-2Kb chimeric MHC class I molecule (Int. J. Cancer: 100, 565, 2002) would be stably expressed. The target cells were labeled with 51Cr at 3.7 Mbq/106 cells, after which the aforementioned peptide was added to obtain a concentration of 100 gg/mL, and the cells were further pulsed for 1 hour. The target cells, but not pulsed with the peptide (non-pulsed), were labeled with 51Cr for 2 hours and used as control target cells. These labeled target cells and previously prepared splenocytes were mixed in a ratio of 1:80 and cultured for 4 hours, and CTL activity was calculated from the ratio of target cells injured. The results are shown in Figure 1.
As shown in Figure 1, in the groups receiving the cancer vaccine composition of the present invention, the target cells pulsed with the peptide were severely injured, but the control target cells not pulsed with the peptide were less injured;
therefore, it was demonstrated that peptide specific CTL was induced. On the other hand, in the groups receiving the cancer vaccines 37, 38, 39, and 45, the group receiving the peptide emulsion prepared with IFA, and the group receiving the peptide alone, the cytotoxicity was low, and the CTL induction activity was low. From this finding, it is evident that the emulsified composition for dilution of the present invention activates in vivo CTL induction when combined with cancer antigen peptides.
It is also shown that the choice of the ingredient A of the present invention and the molar number of ethylene oxide adduct to the ingredient B influence CTL induction activity.
[Test Example 3]
<CTL induction with cancer vaccine composition comprising MAGE-1 peptide>
The specific CTL induction potential of the cancer vaccine composition comprising the MAGE-1 peptide, prepared in Test ak 02595063 2007-07-17 Example 1, was evaluated in the same manner as Test Example 2.
To prepare cancer vaccine compositions, the emulsified compositions 8, 37, 38, and 45 were used. The cancer vaccine compositions prepared were given the same numbers as the emulsified compositions. In the evaluation, separately from Test Example 1, groups receiving an emulsion comprising the MAGE-1 peptide, prepared using incomplete Freund's adjuvant (IFA, purchased from Wako Pure Chemical Industries, Ltd.), or the peptide water phase alone, as the dosing liquid, were /0 established, and compared with groups receiving each cancer vaccine composition as the dosing liquid. The results are shown in Figure 2.
As shown in Figure 2, in the group receiving the cancer vaccine composition of the present invention, the target cells pulsed with the peptide were severely injured, but the control target cells not pulsed with the peptide were less injured;
therefore, it was demonstrated that peptide specific CTL was induced. On the other hand, in the groups receiving the cancer vaccines 37, 38, and 45, the group receiving the peptide emulsions prepared with IFA, and the group receiving the peptide alone, the cytotoxicity was low, and the CTL induction activity was low. These results are similar to those of Test Example 2, demonstrating the utility of the emulsified composition for dilution of the present invention.
[Test Example 4]
<CTL induction with cancer vaccine composition comprising the PSA peptide (1)>
The specific CTL induction potential of the cancer vaccine composition comprising the PSA peptide, prepared in Test Example 1, was evaluated in the same manner as Test Example 2.
To prepare cancer vaccine compositions, the emulsified compositions 2, 7, 10, 29, and 38 were used. The cancer vaccine compositions prepared were given the same numbers as the emulsified compositions. Also, using the emulsified composition 7, 700 L of the emulsified composition and 300 IAL of water for ak 02595063 2007-07-17 injection were mixed according to Test Example 1 to prepare a peptide-free composition, and a comparison was performed. The results are shown in Figure 3.
As shown in Figure 3, in the groups receiving the cancer vaccine composition of the present invention (2, 7, 10, 29), the target cells pulsed with the peptide were severely injured, but the control target cells not pulsed with the peptide were less injured; therefore, it was demonstrated that peptide specific CTL was induced. On the other hand, in the group receiving the cancer vaccine 38, the cytotoxicity was low, and the CTL
induction activity was low. In the group receiving the peptide-free composition, absolutely no cytotoxicity was observed, demonstrating that the emulsified composition alone does not have the activity to induce CTL. These results are similar to those of Test Example 2, demonstrating the utility of the emulsified composition for dilution of the present invention.
[Test Example 5]
<CTL induction with cancer vaccine composition comprising PSA
peptide (2)>
The specific CTL induction potential of the cancer vaccine composition comprising the PSA peptide, prepared in Test Example 1, was evaluated in the same manner as Test Example 4.
To prepare cancer vaccine compositions, the emulsified compositions 16, 17, and 20 were used. The cancer vaccine compositions prepared were given the same numbers as the emulsified compositions. In the evaluation, separately from Test Example 1, a group receiving an emulsion comprising the PSA
peptide, prepared using incomplete Freund's adjuvant (IFA, purchased from Wako Pure Chemical Industries, Ltd.) as the dosing liquid, was established, and compared with groups receiving each cancer vaccine composition as the dosing liquid.
The results are shown in Figure 4.
As shown in Figure 4, in the group receiving the cancer vaccine composition of the present invention, the target cells pulsed with the peptide were severely injured, but the control ak 02595063 2007-07-17 target cells not pulsed with the peptide were less injured;
therefore, it was demonstrated that peptide specific CTL was induced. When the PSA peptide was used, even in the group receiving the peptide emulsion prepared with IFA, peptide specific CTL was induced. From this result and the results of Test Examples 2 and 3, it was shown that IFA, which is conventionally known, activated CTL induction in some cancer antigen peptides, but that this activation was significantly influenced by the kind of peptide, and that IFA is insufficient in versatility.
[Test Example 61 <CTL induction with cancer vaccine composition comprising CEA
peptide>
The specific CTL induction potential of the CEA-containing cancer vaccine composition prepared in the Test Example 1 was evaluated in the same manner as Test Example 2.
To prepare cancer vaccine compositions, the emulsified compositions 12, 13, 28, 29, 30, 37, and 38 were used. The cancer vaccine compositions prepared were given the same numbers as the emulsified compositions. The results are shown in Figure 5. As shown in Figure 5, in the groups receiving a cancer vaccine composition prepared using the emulsified composition of the present invention (12, 13, 28, 29), the target cells pulsed with the peptide were severely injured, but the control target cells not pulsed with the peptide were less injured; therefore, it was demonstrated that peptide specific CTL was induced. On the other hand, in the groups receiving the cancer vaccines 37 and 38, the cytotoxicity was low, and the CTL induction activity was low. These results are similar to those of Test Example 2, demonstrating the utility of the emulsified composition for dilution of the present invention.
[Test Example 7]
<CTL induction with cancer vaccine compositions comprising various cancer antigen peptides>
Using the emulsified composition 21, the specific CTL

ak 02595063 2007-07-17 induction potentials of the cancer vaccine compositions comprising each of the TERT, MAGE-1, and CEA peptides, prepared according to Test Example 1, were evaluated in the same manner as Test Example 2. The results are shown in Figure 6. According to Figure 6, in the group receiving a cancer vaccine composition prepared using the emulsified composition of the present invention, the target cells pulsed with the peptide were severely injured, but the control target cells not pulsed with the peptide were less injured; therefore, it was demonstrated that peptide specific CTL was induced.
These results show that the emulsified composition for dilution of the present invention activates CTL induction specific for each cancer antigen in vivo when combined with various cancer antigen peptides.
[Test Example 8]
<Evaluation of stability of emulsified compositions for dilution>
Emulsified compositions for dilution prepared in Examples were tested for stability. For the test, the emulsified compositions 1 to 39, 56, and 57, which showed no apparent separation when allowed to stand for 24 hours after preparation, were used. Specifically, 2 mL of each emulsified composition was filled in a glass vial of 4 mL capacity, and the vial was tightly closed and stored at 25 C for 1 month, 3 months, and 6 months, after which each composition was examined for apparent change. As a result, no apparent change was observed in any of the emulsified compositions.
[Test Example 9]
<Microscopic examination of emulsified compositions for dilution>
In the same manner as Test Example 8, the emulsified compositions showing no apparent separation when allowed to stand for 24 hours after preparation (1 to 39, 56, 57) were used to microscopically examine the emulsified state both before and after dilution. First, the emulsified state of each emulsified ak 02595063 2007-07-17 composition was examined using a phase contrast microscope at 200-fold magnification. As a result, all emulsified compositions exhibited a fine good emulsified state. Hence, 700 of each emulsified composition and 300 III, of water for injection were taken in cryogenic vial inner cap type of 5 mL capacity (manufactured by Sumitomo Bakelite Co., Ltd.), and stirred using a shikenkan mixer (Touch Mixer MT-51, manufactured by Yamato Scientific Co., Ltd.) for 2 minutes, after which each composition was examined for emulsified state under microscope in the same manner as above. As a result, the emulsified compositions 1 to 35 exhibited a fine good emulsified state, whereas the emulsified compositions 36 to 39, 56 and 57 exhibited evident aggregation of water phase particles.
[Test Example 10]
<Evaluation of average particle diameters of emulsified compositions for dilution>
Of the emulsified compositions for dilution obtained in the Examples and Comparative Examples, the emulsified compositions 1, 2, 4, 6, 7, 8, 10, 21, 29, 36, and 39 were tested to determine the average particle diameters thereof.
Measurements were performed by the dynamic light scattering method using a particle size distribution analyzer (ZETA-SIZER
NANO-S, manufactured by MALVERN INSTRUMENTS Company). To ensure accurate measurements, each emulsified composition was diluted as appropriate with a continual phase of ethyl oleate at the time of measurement. The results are shown in Table 14. Each average particle diameter is the mean of all particle diameters calculated from the light scattering intensity. As examples of the measurement results, the particle size distributions of the emulsified compositions 8 and 29 at the time of preparation (initial) are shown in Figures 7 and 8, respectively.

ak 02595063 2007-07-17 Table 14 Average particle diameter (nm) Emulsified At time of After storage at 5 C
composition preparation for 3 months (initial) 39 160 ________________________________________ As a result of the measurements, all emulsified compositions had an average particle diameter in the range of 50 5 to 500 nm at the time of preparation. From this finding, it is seen that simply exhibiting a good emulsified state is insufficient to use for diluting cancer antigen peptides. Hence, this data showed that what is essential to the CTL induction potential of the emulsified composition for dilution of the 10 present invention is not "to be capable of preparing a good emulsified composition", but for the molar number of ethylene oxide adduct to the ingredient B nonionic surfactant to fall in a particular range.
For the emulsified compositions 1, 2, 4, 6, 7, 8, 10, 21, and 29 out of the above-described emulsified compositions for dilution, average particle diameters after storage at 5 C for 3 months were measured in the same manner. As a result, no major change in average particle diameter was observed in any of the emulsified compositions; therefore, it is seen that the emulsified composition for dilution of the present invention is also excellent in low-temperature stability.
[Test Example 11]
<CTL induction with cancer vaccine compositions comprising a mixture of two kinds of cancer antigen peptide>

Cancer vaccine compositions comprising each of mixtures of two kinds of peptides, i.e., MAGE-1 and CEA, TERT and CEA, and CEA and PSA, out of the cancer antigen peptides described in Table 13, were prepared, and the specific CTL induction potentials thereof were evaluated.
Each cancer vaccine composition was prepared using the emulsified composition 4, specifically as described below.
First, each of the MAGE-1, CEA, TERT, and PSA peptides was prepared as a 100 mg/mL DMS0 solution. Next, each of the combinations of MAGE-1 and CEA, TERT and CEA, CEA and PSA in DMSO solution was mixed, and each mixture was diluted using water for injection to obtain a concentration of 2 mg/600 gL for each peptide to yield peptide mixed solutions (4 mg/600 gL as the total amount of peptide). After preparation of each solution, the absence of precipitate was visually confirmed. Separately, emulsified compositions obtained in Examples were thoroughly mixed using a shikenkan mixer (Touch Mixer MT-51, manufactured by Yamato Scientific Co., Ltd.) (fully stirred and homogenized before use).
Next, 700 gL of the emulsified composition was collected in cryogenic vial inner cap type of 5 mL capacity (manufactured by Sumitomo Bakelite Co., Ltd.) using a 1000 gL Eppendorf pipette. Next, while stirring the tube using the shikenkan mixer, 300 gL of the above-described peptide mixed solution was added drop by drop, and mixed. The stirring speed of the shikenkan mixer was set at the maximum level. After the peptide mixed solution was added drop by drop, the mixture was further stirred for 2 minutes using the shikenkan mixer to yield three kinds of cancer vaccine compositions (MAGE-1/CEA mixture, TERT/CEA
mixture, CEA/PSA mixture).
The specific CTL induction potentials of the three kinds of cancer vaccine composition prepared were evaluated using HLA-A24 transgenic mice (Int. J. Cancer: 100, 565, 2002).
200 gL of each dosing liquid (each peptide dose of 200 jig x 2 kinds) was subcutaneously administered to the tail root of ak 02595063 2007-07-17 each HLA-A24/Kb transgenic mouse. One mouse was used for each group. Seven days after administration, the spleen was extirpated and splenocytes were prepared. Some of the splenocytes were pulsed with 50 ilg/mL of each of two kinds of subject peptides (100 pg/mL in total) for 1 hour. Splenocytes not pulsed with the peptides were sown to a 24-well plate at 7 x 106 cells/well, and the above-mentioned splenocytes pulsed with the peptide were further added at 7 x 105 cells/well and cultured.
The culture broth comprised an RPMI1640 medium supplemented with 10% FCS, 10 mM HEPES, 20 mM L-glutamine, 1 mM sodium pyruvate, 1 mM MEM non-essential amino acids, 1% MEM vitamin, and 55 11M 2-mercaptoethanol, and the cells were cultured for 5 days. The CTL
activity specific for the peptide administered in the cultured splenocytes was measured by 51Cr release assay (J. Immunol.: 159, 4753, 1997). The target cells used were cells of the cell line EL4-A2402/Kb prepared by transferring a gene to mouse lymphoma-derived cell line EL-4 cells (ATCC line number TIB-39) so that the HLA-A24 and H-2Kb chimeric MHC class I molecule (Int. J.
Cancer: 100, 565, 2002) would be stably expressed. The target cells were labeled with 51Cr at 3.7 Mbq/106 cells, after which each peptide was added to obtain a concentration of 100 10/mL, and the cells were pulsed for 1 hour. Target cells not pulsed with the peptide (non-pulsed) were labeled with 51Cr for 2 hours and served as control target cells. These labeled target cells and previously prepared splenocytes were mixed in a ratio of 1:80 and cultured for 4 hours, and CTL activity was determined from the ratio of target cells injured. The results are shown in Figure 9.
As shown in Figure 9, in the groups receiving cancer vaccine compositions prepared using the emulsified composition for dilution of the present invention, the target cells pulsed with the peptides were severely injured. On the other hand, the control target cells not pulsed with the peptides were less injured; therefore, it was demonstrated that when two kinds of cancer antigen peptide were mixed, CTL specific for each peptide was concurrently induced. From this finding, it was demonstrated that the emulsified composition for dilution of the present invention activates CTL induction in vivo when combined with various cancer antigen peptides.
Industrial Applicability The emulsified composition for dilution of the present invention is a stable WO emulsion per se. By diluting a cancer antigen peptide or a dimer thereof with the emulsified composition for dilution of the present invention by a simple operation, there is provided a cancer vaccine composition that is a stable WO emulsion exhibiting CTL induction activity specific for each cancer antigen in vivo.
The present invention also provides an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, intended to induce specific CTL. Also provided by this emulsified composition for dilution is a cancer vaccine composition having CTL induction activity specific for various cancer antigens in vivo. The present invention is considered to be effective in ameliorating conditions in many cancer patients.
This application is based on a patent application No.
2005-012140 filed in Japan on January 19, 2005.

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (27)

CLAIMS:
1. An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water.
2. An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;

(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water;
wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm.
3. An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, consisting essentially of:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water;
wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm.
4. An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, consisting of:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water;
wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm.
5. The emulsified composition of any one of claims 2 to 4 in which the ester of (A) constitutes 60-80% by weight.
6. The emulsified composition of any one of claims 2 to 5 in which the nonionic surfactant of (B) constitutes 1-10%
by weight.
7. The emulsified composition of any one of claims 2 to 6 in which the emulsifier of (C) constitutes 5-15% by weight.
8. The emulsified composition of any one of claims 2 to 6 in which the emulsifier of (C) constitutes 1-20% by weight.
9. The emulsified composition of any one of claims 2 to 8, wherein the fatty acid of (A) is oleic acid, myristic acid or 2-ethylhexanoic acid.
10. The emulsified composition of any one of claims 2 to 8, wherein the ester of (A) is ethyl oleate, octyldodecyl myristate or cetyl 2-ethylhexanoate.
11. The emulsified composition of any one of claims 2 to 8 wherein the ester of (A) is ethyl oleate, octyldodecyl myristate or a combination thereof.
12. The emulsified composition of any one of claims 2 to 11, wherein the hydroxy fatty acid triglyceride of (B) is castor oil or hardened castor oil.
13. The emulsified composition of any one of claims 2 to 11, wherein the hydroxy fatty acid triglyceride of (B) is hardened castor oil adduct with 20 mol of ethylene oxide.
14. The emulsified composition of any one of claims 2 to 13 wherein the emulsifier of (C) is glycerin monooleate, sorbitan monooleate, or a combination thereof.
15. The emulsified composition of any one of claims 2 to 4, wherein the nonionic surfactant of (B) consists of a hardened castor oil adduct with 10 to 20 mol of ethylene oxide.
16. A cancer vaccine composition comprising:
(A) 30 to 80% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 10 to 60% by weight of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof;
wherein the composition is a 1,00 emulsion.
17. The cancer vaccine composition of claim 16, comprising:
40 to 60% by weight of the ester of (A);
0.5 to 20% by weight of the nonionic surfactant of (B);
to 10% by weight of the emulsifier of (C); and 30 to 50% by weight of the water phase of (D).
18. The cancer vaccine composition of claim 16 or 17 wherein the ester of (A) is ethyl oleate, octyldodecyl myristate or a combination thereof.
19. The cancer vaccine composition of any one of claims 16 to 18, wherein the hydroxy fatty acid triglyceride of (B) is hardened castor oil adduct with 20 mol of ethylene oxide.
20. The cancer vaccine composition of any one of claims 16 to 19 wherein the emulsifier of (C) is glycerin monooleate, sorbitan monooleate, or a combination thereof.
21. A cancer vaccine composition which is a W/O emulsion obtained by diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of the emulsified composition of any one of claims 1 to 15.
22. A specific cytotoxic T cell inducer comprising:
(A) 30 to 80% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 1 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 10 to 60% by weight of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof;
wherein the composition is a W/O emulsion.
23. The specific cytotoxic T cell inducer of claim 22, comprising:
40 to 60% by weight of the ester of (A);
0.5 to 20% by weight of the nonionic surfactant of (B);
to 10% by weight of the emulsifier of (C); and 30 to 50% by weight of the water phase of (D).
24. A specific cytotoxic T cell inducer which is a W/O
emulsion obtained by diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with 1 part by volume of an emulsified composition of any one of claims 1 to 15.
25. A kit for freshly preparing a cancer vaccine composition, comprising a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, and an emulsified composition for diluting the water phase, wherein the emulsified composition comprises:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;

(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water.
26. A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of an emulsified composition comprising:
(A) 50 to 90% by weight of an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10°C;
(B) 0.5 to 20% by weight of a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide;
(C) 0 to 20% by weight of an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40°C; and (D) 5 to 20% by weight of water.
27. A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, with 1 part by volume of the emulsified composition of any one of claims 1 to 15.
CA2595063A 2005-01-19 2006-01-19 Emulsified composition for dilution and cancer vaccine composition Active CA2595063C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005012140 2005-01-19
JP2005-012140 2005-01-19
PCT/JP2006/301171 WO2006078059A1 (en) 2005-01-19 2006-01-19 Emulsified composition for dilution and cancer vaccine composition

Publications (2)

Publication Number Publication Date
CA2595063A1 CA2595063A1 (en) 2006-07-27
CA2595063C true CA2595063C (en) 2014-07-08

Family

ID=36692424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2595063A Active CA2595063C (en) 2005-01-19 2006-01-19 Emulsified composition for dilution and cancer vaccine composition

Country Status (9)

Country Link
US (2) US8178102B2 (en)
EP (2) EP1844789B8 (en)
JP (1) JP5084268B2 (en)
KR (1) KR101322586B1 (en)
CN (1) CN101111258B (en)
AU (1) AU2006206973C1 (en)
CA (1) CA2595063C (en)
ES (1) ES2507097T3 (en)
WO (1) WO2006078059A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1844789B8 (en) * 2005-01-19 2014-10-08 Sumitomo Dainippon Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
KR100900837B1 (en) 2007-12-07 2009-06-04 (주)두비엘 A powerful vaccine composition comprising lipopeptide and poly(i:c) as an adjuvant
KR20140099828A (en) * 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 Vaccine composition for mucosal administration
RU2014102939A (en) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Vaccine composition for transdermal administration
WO2014157704A1 (en) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Conjugate vaccine using trimming function of erap1
CA2907782C (en) 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 helper peptide, and combination of said peptide and cancer antigen peptide conjugate
WO2018181648A1 (en) 2017-03-30 2018-10-04 大日本住友製薬株式会社 Wt1 cancer antigen peptide and peptide conjugate body containing same
KR20210068060A (en) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 composition for injection
EP3954382A4 (en) 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. Water soluble adjuvant and composition containing same
CN113966326A (en) 2019-04-05 2022-01-21 大日本住友制药株式会社 Water soluble adjuvants
TW202200188A (en) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 Pharmaceutical composition for treating cancer
TW202315645A (en) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0247474A (en) 1988-08-04 1990-02-16 Aisan Ind Co Ltd Parking tower device
JPH085401B2 (en) * 1990-05-18 1996-01-24 株式会社丸山製作所 Braking device for self-propelled vehicles
EP0580778B1 (en) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
JPH0620071A (en) 1992-07-03 1994-01-28 Sharp Corp Data driven information processor
FR2702373B1 (en) * 1993-03-08 1996-06-07 Rhone Merieux Water-in-oil fluid vaccine emulsions containing a metabolizable oil.
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
JP4104186B2 (en) 1995-11-30 2008-06-18 財団法人化学及血清療法研究所 Oil adjuvant vaccine and preparation method thereof
DE69636889T2 (en) * 1995-11-30 2007-12-06 Nof Corp. Oil-filled vaccine and process for its preparation
JP4113990B2 (en) 1996-07-05 2008-07-09 宮崎県 Anticancer agent-containing emulsion preparation and method for producing the same
JP4375773B2 (en) 1998-04-20 2009-12-02 塩野義製薬株式会社 Th2 migration promoter containing W / O emulsion
CA2352563C (en) * 1998-12-21 2010-08-17 Akzo Nobel N.V. Method to produce inactivated w/o emulsion adjuvanted vaccines
FR2800280B1 (en) 1999-10-29 2003-09-19 Seppic Sa NOVEL VACCINE COMPOSITION AND USE OF SURFACTANTS AS IMMUNITY ADJUVANTS
JP2001131087A (en) 1999-11-05 2001-05-15 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
EP1844789B8 (en) * 2005-01-19 2014-10-08 Sumitomo Dainippon Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition

Also Published As

Publication number Publication date
AU2006206973A1 (en) 2006-07-27
ES2507097T3 (en) 2014-10-14
EP1844789B8 (en) 2014-10-08
EP1844789B1 (en) 2014-07-23
WO2006078059A1 (en) 2006-07-27
US8178102B2 (en) 2012-05-15
KR101322586B1 (en) 2013-10-25
EP1844789A1 (en) 2007-10-17
CN101111258A (en) 2008-01-23
EP2687203A1 (en) 2014-01-22
JP5084268B2 (en) 2012-11-28
US20120237569A1 (en) 2012-09-20
EP1844789A4 (en) 2009-10-28
CA2595063A1 (en) 2006-07-27
AU2006206973C1 (en) 2012-06-28
US20090136572A1 (en) 2009-05-28
CN101111258B (en) 2011-07-06
AU2006206973B2 (en) 2010-09-30
KR20070104610A (en) 2007-10-26
JPWO2006078059A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
CA2595063C (en) Emulsified composition for dilution and cancer vaccine composition
US20230233658A1 (en) Formulation of a peptide vaccine
AU2009201589C1 (en) Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
JP5921395B2 (en) Novel composition of tumor associated peptides that bind to human leukocyte antigen (HLA) class I or II molecules for vaccine use
NZ789530A (en) Formulation of a peptide vaccine

Legal Events

Date Code Title Description
EEER Examination request